In hepatocellular carcinoma, LINC00152 appears to activate the rapamycin (mTOR) pathway by binding to the promoter of EpCAM through cis-regulation, which was confirmed by the Gal4-λN/BoxB reporter system16. Here, MLPH is linked to hepatocellular carcinoma.